logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Kala Pharmaceuticals, Inc.

USPTO Granted Patents = 53

% Expired Patents = 43.4



Trademarks = 1

Forward Citations = 217

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Winston Zapanta Ong (46 out of 47 patents)

silverMedal Pawel Wojciech Nowak (30 out of 31 patents)

bronzeMedal Jinsoo Kim (23 out of 23 patents)

4.  Elizabeth M Enlow (19 out of 38 patents)

5.  Minh Ngoc Nguyen (18 out of 18 patents)

6.  Ben C Askew (15 out of 52 patents)

7.  Alexey Popov (9 out of 30 patents)

8.  John Thomas Feutrill (8 out of 8 patents)

9.  Hongming Chen (7 out of 26 patents)

10.  James Bourassa (7 out of 26 patents)

11.  Justin Scot Hanes (5 out of 71 patents)

12.  Colin R Gardner (4 out of 13 patents)

13.  Laura M Ensign (4 out of 20 patents)

14.  Tao Yu (4 out of 13 patents)

15.  Ming Yang (4 out of 16 patents)


Core Competencies:
Therapeutic Compounds
Urea Derivatives
Nanocrystals
Poly(vinyl Alcohol)
Particle Transport
VEGFR2 Inhibitors
Crystalline Forms
Meropenem Derivatives
Biochemical Binding
Functionalized Copolymers
Polymer Compositions
Drug Delivery

53 patents:

1. 11713323 - Crystalline forms of therapeutic compounds and uses thereof (2023-08-01),
2. 11401260 - Biochemical binding of RET9 and VEGFR2 inhibitors (2022-08-02),
3. 11369611 - Therapeutic compounds and uses thereof (2022-06-28),
4. 11352343 - Urea derivatives and uses thereof (2022-06-07),
5. 11318088 - Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus (2022-05-03),
6. 11104685 - Crystalline forms of therapeutic compounds and uses thereof (2021-08-31),
7. 11091487 - Meropenem derivatives and uses thereof (2021-08-17),
8. 11021487 - Crystalline forms of therapeutic compounds and uses thereof (2021-06-01),
9. 10975090 - Crystalline forms of therapeutic compounds and uses thereof (2021-04-13),
10. 10966987 - Therapeutic compounds and uses thereof (2021-04-06),
11. 10954244 - Compounds and uses thereof (2021-03-23),
12. 10875857 - 1-amino-triazolo(1,5-A)pyridine-substituted urea derivative and uses thereof (2020-12-29),
13. 10766907 - Crystalline forms of therapeutic compounds and uses thereof (2020-09-08),
14. 10758539 - Therapeutic compounds and uses thereof (2020-09-01),
15. 10723719 - Urea derivatives and uses thereof (2020-07-28),
Company Overview
Kala Pharmaceuticals, Inc., based in Waltham, MA, specializes in the development of innovative therapeutic compounds aimed at addressing unmet medical needs. The company focuses on advanced pharmaceutical chemistry, leveraging technologies such as urea derivatives and nanocrystals to enhance drug delivery and efficacy. Key areas of research include particle transport mechanisms and the development of crystalline forms of compounds, including VEGFR2 inhibitors and meropenem derivatives, to improve treatment outcomes in various therapeutic areas.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Kala Pharmaceuticals, Inc. USPTO Patent Assignee Logo
53 Patents

#32 in Waltham, MA

#378 in Massachusetts

#6,672 in US

#13,348 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Kala Pharmaceuticals, Inc.

Forward Citations = 217

21 inventors:

goldMedal Winston Zapanta Ong (46 out of 47 patents)

silverMedal Pawel Wojciech Nowak (30 out of 31 patents)

bronzeMedal Jinsoo Kim (23 out of 23 patents)

4.  Elizabeth M Enlow (19 out of 38 patents)

5.  Minh Ngoc Nguyen (18 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kala Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/kala-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…